BioAge Labs (BIOA) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed BioAge Labs (BIOA) over the past year, gaining 166.0% versus a gain of 11.8%. Prelude Therapeutics is the larger company by market cap ($305.6 million vs $287.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | PRLD |
|---|---|---|
| Share price | $6.26 | $3.83 |
| Market cap | $287.31M | $305.65M |
| 1-day change | -0.48% | +0.52% |
| YTD return | -52.68% | +32.07% |
| 1-year return | +11.79% | +165.97% |
| 5-year return | — | -76.45% |
| EPS (TTM) | $-2.39 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.96 | $6.83 |
| 52-week low | $5.04 | $1.15 |
| Distance from 52-week high | -75.88% | -43.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +469.17% | +140.21% |
| Average volume | 915.59K | 477.81K |
| Shares outstanding | 45.90M | 65.08M |
| Employees | 60 | 79 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed BIOA by 154.2 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Healthcare · Drug Manufacturers - Specialty & Generic · 60 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Healthcare · Biotechnology · 79 employees
BIOA vs PRLD FAQ
Which is bigger, BioAge Labs or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $305.65M compared with $287.31M for BioAge Labs (BIOA).
Which stock has performed better over the past year, BIOA or PRLD?
PRLD returned +165.97% over the past 12 months, compared with +11.79% for BIOA (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Prelude Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for BioAge Labs and Biotechnology for Prelude Therapeutics.